Trevi Therapeutics: The Code Against Chronic Cough
Reading Time: 3 minutes
Trevi Therapeutics has approximately $334 million in liquid assets thanks to successful capital increases, meaning the company is fully financed until 2030 and is not at risk of short-term dilution. With the promising candidate Haduvio , the company is aiming for a potential approval monopoly in an untapped billion-dollar market for chronic cough. Despite top-notch study data, the stock remains a highly speculative bet for risk-seeking investors. The U.S. biotech stock Trevi Therapeutics (NASDAQ: TRVI) is surging from one high to...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
